Lewis & Vlak

McNicoll, Lewis & Vlak maintained its Icagen (NASDAQ: ICGN) Hold rating in a research report published today. In the report, McNicoll, Lewis & Vlak states, "We maintain our hold rating as ICGN prepares for its acquisition by Pfizer. It should be noted that ICGN's second largest shareholder...

McNicoll, Lewis & Vlak reiterated its Corcept Therapeutics (NASDAQ: CORT) Buy rating and $8 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "We have assumed that CORLUX will obtain US approval in 1H:12 and have conservatively assumed parity...

McNicoll, Lewis & Vlak reiterated its Inhibitex (NASDAQ: INHX) Buy rating and $7 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "We reiterate our BUY rating and $7 price target. INHX plans to actively engage the FDA in designing a Phase IIb...

McNicoll, Lewis & Vlak reiterated its Rockwell Medical (NASDAQ: RMTI) Buy rating and $16.50 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "RMTI recently purchased an ANDA for generic injectable Vitamin-D known as Calcitriol. RMTI expects...

McNicoll, Lewis & Vlak lowered its SuperGen (NASDAQ: SUPG) price target from $8 to $6.50 and maintained its SuperGen Buy rating in a research report published today. In the report, McNicoll, Lewis & Vlak states, "We expect significant changes in SuperGen's pipeline following a portfolio...

McNicoll, Lewis & Vlak reiterated its Vivus (NASDAQ: VVUS) Buy rating and $16 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "Although FORTRESS will have a greater number of dyads (mother-infant pairs), it will be similar in methodology and...

McNicoll, Lewis & Vlak maintained its SuperGen (NASDAQ: SUPG) Buy rating and $8 price target after SuperGen's acquisition announcement of Astex Therapeutics in a research report published today. In the report, MLV states, "We expect SuperGen to provide an update on corporate structure and...

McNicoll, Lewis & Vlak reiterated its Alnylam Pharmaceuticals (NASDAQ: ALNY) Buy rating and $15 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "In our opinion, RNAi represents the next major therapeutic class; it has the potential to...